6533b82dfe1ef96bd1290905
RESEARCH PRODUCT
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
R. LabiancaFortunato CiardielloJ.-y. DouillardAlfredo FalconeAndré D'hooreC.-h. KöhneAziz ZaananGeorge PentheroudakisDan AderkaNicola NormannoTakayuki YoshinoPer PfeifferH.-j. SchmollAl B. BensonJ.h.j.m. Van KriekenRené AdamDemetris PapamichaelPaulo M. HoffJens RickeR. SalazarGyörgy BodokyHarpreet WasanJosep TaberneroTimothy J. PriceDirk ArnoldMichel DucreuxAlberto SobreroThomas GruenbergerBrigette B.y. MaAxel GrotheyE. Aranda AguilarE. Van CutsemKarin HaustermansVolker HeinemannPia ÖSterlundPia ÖSterlundKei MuroArnaud RothEduardo Díaz-rubioPierre Laurent-puigAndrés CervantesAlberto BardelliWim J.g. OyenJulien TaiebC.j.a. PuntSabine TejparTim MaughanWerner Scheithauersubject
0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practiceBevacizumabColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Guidelines as Topiccolorectal cancerRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]03 medical and health scienceschemistry.chemical_compoundClinical practice guidelines; Colorectal cancer; Consensus; ESMO; Hematology; Oncology0302 clinical medicineGuia de Práctica ClínicaInternal medicineBiomarkers TumormedicineHumansMolecular Targeted TherapyNeoplasm MetastasisIntensive care medicineTipiracilNeoplasias Colorrectais/tratamentoFOLFOXIRIbusiness.industryESMO; clinical practice guidelines; colorectal cancer; consensusCancerHematologyESMOPrognosismedicine.diseaseDebulkingChemotherapy regimendigestive system diseases3. Good health030104 developmental biologyPractice GuidelineOncologychemistryColorectal Neoplasms/therapyconsensus030220 oncology & carcinogenesisColorectal Neoplasmsbusinessclinical practice guidelinesclinical practice guidelinemedicine.drugdescription
Contains fulltext : 165965.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-07-05 |